Hepatocyte growth factor/scatter factor (HGF/SF) induces scattering and morphogenesis of epithelial cells through the activation of the MET tyrosine kinase receptor. Although the activated MET receptor recruits a number of signaling proteins, little is known of the downstream signaling pathways activated by HGF/SF. In this study, we wished to examine the signaling pathway leading to activation of the ETS1 transcription factor. Using in vitro and in vivo kinase assays, we found that HGF/SF activates the ERK1 MAP kinase, leading to the phosphorylation of the threonine 38 residue of ETS1 within a putative MAP kinase phosphorylation site (PLLT38P). This threonine residue was neither phosphorylated by JNK1, nor by p38 MAP kinases and was required for the induction of transcriptional activity of ETS1 by HGF/SF. Using kinase and transcription assays, we further demonstrated that phosphorylation and activation of ETS1 occurs downstream of a RAS-RAF-MEK-ERK pathway. The functional involvement of this pathway in HGF/SF action was demonstrated using U0126, a pharmacological inhibitor of MEK, which blocked phosphorylation and activation of ETS1, RASdependent transcriptional responses, cell scattering and morphogenesis. These data demonstrated that ETS1 is a downstream target of HGF/SF acting through a RAS-RAF-MEK-ERK pathway and provides a signaling pathway leading to the regulation of gene expression by HGF/SF.
Introduction
The hepatocyte growth factor/scatter factor/(HGF/SF) is a mesenchymal factor that stimulates proliferation, scattering and morphogenesis of epithelial cells through the c-MET tyrosine kinase receptor (Nakamura et al., 1984; Naldini et al., 1991; Weidner et al., 1993) . Binding of HGF/SF to the c-MET receptor triggers its dimerization and autophosphorylation; this leads to the recruitment and activation of a number of intracellular proteins (see Furge et al., 2000) . Several of these proteins, including GAB1, GRB2 and SHC, can elicit the activation of the RAS guanine nucleotide binding protein, which appears to play a major role in mediating the biological eects of HGF/SF. Infection of MDCK cells with a RAS-transducing retrovirus induced cell scattering (Behrens et al., 1989) , whereas an inducible dominant negative form of RAS prevented the motility signal of HGF/SF (Hartmann et al., 1994) . RAS is also required for the induction of morphogenesis of epithelial cells, although overexpression of RAS led to invasive growth, rather than to proper branching tubulogenesis (Khwaja et al., 1998; Terauchi and Kitamura, 2000) .
The activated RAS ± GTP complex is capable of directly associating with kinases and thereby initiating protein kinase cascades. For example, RAS ± GTP forms a complex with the MAP kinase kinase RAF, resulting in the translocation of this kinase to the cell surface and activation of RAF kinase activity (Marais et al., 1995) . The RAF kinase then activates the MEK MAP kinase, which in turn activates the ERK1,2 MAP kinase (Howe et al., 1992) . A similar mechanism probably leads to the activation of the MAP kinase kinase-1/MAP kinase 4,7/JNK kinase in some cell types (Minden et al., 1994) . The RAS ± GTP complex also associates with the PI3 kinase in some model systems (Kodaki et al., 1994) . Therefore, RAS may activate at least three, and probably multiple protein kinase cascades. Of interest, these protein kinase cascades can lead to the activation of speci®c transcription factors and to the regulation of gene expression.
We previously found that the expression of the ETS1 transcription factor is induced by HGF/SF and that this factor mediates transcription by HGF/SF through a RAS-responsive element constituted by combined binding sites for the ETS and AP1 family of transcription factors (Fafeur et al., 1997) . Such RASresponse elements are found in a number of promoters or enhancers of cellular genes, including urokinase plasminogene activator (uPA) and collagenase 1, two matrix degrading proteases genes, which can facilitate cell motility in response to HGF/SF (Pepper et al., 1992; Wasylyk et al., 1998) . Nonetheless, the mechanisms leading to ETS1 activation by HGF/SF have not been demonstrated. They can involve activation of MAP kinases and subsequent phosphorylation of ETS1 on a threonine 38 residue lying in a putative MAPK phosphorylation site (Rabault et al., 1996) . This threonine residue was found to be the target of the ERK MAP kinases in vitro (Rabault et al., 1996) , but not in vivo in NIH3T3 cells (Yang et al., 1996) . In addition, the JNK and p38 MAP kinases may also phosphorylate ETS1, as demonstrated for ETS2 and ELK1, two other members of the ETS family (see Yordy and Muise-Helmericks, 2000) . In the present study, we wished to determine the signaling pathway implicating MAP kinases and leading to the phosphorylation and activation of ETS1 by HGF/SF in MDCK epithelial cells.
Results

HGF/SF phosphorylates the ETS1 transcription factor by the ERK1 MAP kinase
Puri®ed and activated ERK1, JNK1 or p38 MAP kinases were tested for their ability to phosphorylate ETS1 by in vitro kinase assays. To this purpose, we constructed a recombinant GST fusion protein containing murine ETS1 (amino acids 1-440, GST-ETS1 1 ± 440 ) (see Figure 1 ). As shown in Figure 2a , ERK1, JNK1 and p38 can phosphorylate ETS1 with distinct eciencies. ERK1 was more ecient than JNK1 to phosphorylate ETS1, while JNK1 was more ecient than p38 to phosphorylate ETS1. The speci®city of action of these kinases was con®rmed using JUN (GST-JUN 1 ± 79 ), a well-known substrate of JNK, and MBP a substrate peptide with multiple phosphorylation sites for MAP kinases. JUN was only phosphorylated by JNK, while MBP was phosphorylated both by ERK1 and p38. Therefore ETS1 can be an in vitro substrate for all three classes of MAP kinases, with ERK1 being more ecient.
We then investigated the ability of HGF/SF to activate these MAP kinases and to phosphorylate ETS1 by in vivo kinase assays using MDCK epithelial cells. Cells were transiently transfected with expression vectors encoding either epitope tagged HA-ERK1, Flag-JNK1 or HA-p38. After 10 min stimulation by HGF/SF and immunoprecipitation of the transfected MAP kinases with their respective speci®c antibodies (HA or Flag), their activities were tested using either GST-ETS1 1 ± 440 , GST-JUN 1 ± 79 or MBP as substrates. In parallel, the level of expression of the transfected kinases was examined by immunoblotting of the corresponding cell lysate using their respective speci®c antibody ( Figure 2b ). Constitutive activity of the three MAP kinases leading to ETS1 phosphorylation was detected in the absence of HGF/SF, with levels varying from experiment to experiment (Figure 2b , see also Figures 5 and 6). Nonetheless, the ability of HGF/SF to activate the three MAP kinases was distinct and the activated kinases show distinct substrate speci®city (Figure 2b ). HGF/SF induced ERK1 activity which increased phosphorylation of ETS1, and induced JNK1 activity which phosphorylated JUN. The activity of p38 was no further induced by HGF/SF using either ETS1 or MBP as a substrate. These activations of ERK and JNK by HGF/SF are in agreement with our previous data showing that ERK and JNK, but not p38 MAP kinase are phosphorylated after HGF/SF treatment (Paumelle et al., 2000) .
The threonine 38 residue of ETS1 is phosphorylated by ERK1
The N-terminal part of ETS1 contains a putative phosphorylation site by MAPK (PLLT38P) (Rabault et al., 1996) . In order to examine this, we performed in vitro kinase assays using as substrates recombinant GST fusion proteins containing the ®rst 68 amino acids of ETS1, with or without substitution of threonine 38 by alanine, a non phosphorylable residue (GST-ETS1 1 ± 68 and GST-ETS1 1 ± 68, T38A ) (see Figure 1 ). As shown in Figure 3a , ERK1 was more ecient than JNK1 or p38 to phosphorylate the N-terminal part of ETS1. Replacement of threonine 38 by an alanine residue decreased the ability of these kinases to phosphorylate ETS1, demonstrating that this residue is a target of phosphorylation by these kinases, in particular ERK1. The weak phosphorylation which is still detected when the threonine residue is mutated might be due to the phosphorylation of a serine residue which is present at position 26 adjacent to a proline residue.
We then investigated in MDCK epithelial cells the ability of HGF/SF to induce the phosphorylation of the threonine 38 residue of ETS1 by in vivo kinase Figure 1 Schematic diagram of ETS1 and of the constructs used in this study. The murine ETS1 protein contains a putative PLLT38P MAP kinase phosphorylation site, a pointed domain (PNT) and a DNA-binding domain (DB). We also reported location of exon VII, which can be removed by alternative splicing. The corresponding amino-acid numbers are indicated. The GST-ETS1 and GAL4-ETS1 constructs, with or without replacement of the threonine 38 residue by alanine (T38A), are described in the text assays. As described above (Figure 2b ), the activity of the MAP kinases was tested following their transient transfection and a 10 min treatment by HGF/SF. Using GST-ETS1 1 ± 68 as a substrate, we found that the N-terminal part of ETS1 was only phosphorylated by ERK1 in response to HGF/SF (Figure 3b ). The lack of phosphorylation of GST-ETS1 1 ± 68, T38A demonstrated that this phosphorylation occurs via the threonine 38 residue of ETS1 (Figure 3b ). It is worth noting that the basal phosphorylation of ETS1 by the three MAP kinases (Figure 2b ) is no longer observed using the N-terminal part of ETS1 (Figure 3b ), indicating that phosphorylation of ETS1 in basal conditions can occur outside of the N-terminal region of ETS1. These kinase assays demonstrated that HGF/ SF activated ERK1, which phosphorylated the threonine 38 residue of ETS1 within the N-terminal region of ETS1.
In order to examine phosphorylation of the threonine 38 residue of ETS1, we used a speci®c anti P-Thr Pro monoclonal antibody which detects phospho-threonine only when followed by proline. Following an in vitro ERK1 kinase assay and immunoblotting of the kinase reaction, this antibody detected phosphorylation of the threonine 38 residue within the PLLT 38 P MAPK phosphorylation site. Indeed, a band was detected when ERK1 kinase activity was tested on GST-ETS1 1 ± 68 , but not when tested on mutated GST-ETS1 1 ± 68, T38A (Figure 3c) . This antibody was then used to detect in vivo phosphorylation of ETS1. MDCK cells were transfected with ETS1 and/or ERK1 and stimulated by HGF/SF for 10 min. After immunoprecipitation of ETS1 with the anti HA-antibody, its phosphorylation was checked by immunoblotting using the anti P-Thr Pro antibody. Upon HGF/SF treatment, a faint band was detected from immunoprecipitates issued from cell lysates transiently transfected both by ERK1 and ETS1 and not when transfected by ETS1 alone (Figure 3d ). This data shows that threonine phosphorylation of ETS1 occurs in response to ERK1 activated by HGF/SF.
The threonine 38 residue of ETS1 confers its transcriptional activity Phosphorylation of the threonine 38 residue can play a role in mediating transcriptional activity of ETS1 in response to HGF/SF. To investigate this, we constructed fusion proteins between the heterologous DNA binding domain of GAL4 (1 ± 147) and the Nterminal region of ETS1 (amino acids 1 to 244, GAL4-ETS1 1 ± 244 ), with or without substitution of threonine 38 by alanine (see Figure 1 ). HGF/SF induced transcriptional activity of ETS1 and the substitution of threonine 38 by an alanine residue decreased the ability of HGF/SF to induce activation of the GAL4-Luc reporter vector ( Figure 4a ). These results indicate that the 1 ± 244 N-terminal part of ETS1 is sucient to confer responsiveness to HGF/SF. Furthermore, the induction of the transcriptional activity of ETS1 by HGF/SF requires phosphorylation of the threonine 38 residue in its N-terminal region.
The role of the phosphorylation of the threonine 38 residue was then investigated in the context of full-length , GST-JUN 1 ± 79 or MBP as substrates. Phosphorylated proteins were separated by 10%-SDS polyacrylamide gel electrophoresis and visualized by autoradiography. Expression of transfected kinases was determined in the cell lysates by immunoblot analysis using either anti-HA (a-HA) or anti-Flag (a-Flag) antibodies ETS1, which can mediate a transcriptional response to HGF/SF implicating an EBS/AP1 response element (Fafeur et al., 1997) . We constructed an expression vector encoding full-length ETS1 (1 ± 440) with or without a substitution of threonine 38 by alanine (ETS 1 ± 440 , ETS1 1 ± 440, T38A ). Co-transfection of wild type ETS1 1 ± 440 or ETS1 1 ± 440, T38A and the EBS/AP1-Luc reporter vector showed that transactivation through the EBS/AP1 promoter element by HGF/SF was potentiated by ETS1 1 ± 440 and not by ETS1 1 ± 440, T38A . These data are in agreement with data shown in Figure 4a . The fact that residual transcriptional activity of ETS1 was found with the mutated ETS1 1 ± 440, T38A indicates that phosphorylation of ETS1 through the threonine 38 residue could not be the sole mechanism leading to transcriptional activation of the EBS/AP1 response element. Other mechanisms can include phosphorylation of ETS1 outside of the PLLTP site and/or interactions of ETS1 with speci®c partners, which in turn contribute to transcriptional activation of the EBS/AP1 response element. Nonetheless our results demonstrate that ETS1 potentiated the eect of HGF/ SF in inducing a transcriptional response and that this potentiation was lost when the threonine 38 was replaced by an alanine residue ( Figure 4b ). These data demonstrate that phosphorylation of the threonine 38 residue of ETS1 is essential in mediating an EBS/AP1 dependent transcriptional response to HGF/SF. In vitro kinase assays. Puri®ed and activated ERK1, JNK1 and p38 were assayed using GST-ETS1 1 ± 68 or GST-ETS1 1 ± 68, T38A as substrates. Phosphorylated proteins were visualized as above. (b) In vivo kinase assays. Cells were transfected with expression vectors encoding HA-ERK1 (ERK1), Flag-JNK1 (JNK1) or HA-p38 (p38) and treated with HGF/SF. Following kinase transfection and treatment by HGF/SF, the kinase activity of immunoprecipitated HA-ERK1, Flag-JNK1 or HA-p38 was assayed using GST-ETS1 1 ± 68 or GST-ETS1 1 ± 68, T38A as substrates. Expression of HA-ERK1, Flag-JNK1 and HA-p38 were detected by immunoblot analysis as above. (c) In vitro phosphorylation of ETS1 by ERK1. Puri®ed and activated ERK1 was assayed in a kinase assay using GST, GST-ETS1 1 ± 68 or GST-ETS1 1 ± 68, T38A as substrates. Phosphorylated proteins were detected by immunoblot analysis using the anti-Phospho Thr Pro (a P-Thr Pro) antibody. Expression of GST fusion proteins were visualized by Coomassie blue staining. (d) In vivo phosphorylation of ETS1 by HGF/SF. Cells were co-transfected with expression vectors encoding either empty (c) or HA-ETS1 (ETS1) with or without HA-ERK1 (ERK1). Following transfection and treatment by HGF/SF, ETS1 and ERK1 were immunoprecipitated from cell lysates with the anti-HA antibody. Phosphorylated proteins were detected by immunoblot analysis using the anti-Phospho Thr Pro (a P-Thr Pro) antibody. The HA-ETS1 protein migrates at a dierent size than the HA-ERK1 protein and its expression was detected by immunoblotting using the anti-HA antibody. The faint band detected when cells were co-transfected with HA-ETS1 and HA-ERK1 and treated by HGF/SF was reproducibly observed ETS1 activation by HGF/SF
HGF/SF activates ETS1 through activation of a RAS-RAF-ERK signaling pathway
In order to identify the pathways that mediate phosphorylation of ETS1 by HGF/SF, we tested dominant negative mutants of RAS, RAF and CDC42 using in vivo kinase assays. Cells were cotransfected with expression vectors encoding either HA-ERK1 or Flag-JNK1 and inactivated forms of RAS (RAS N17 ), RAF (CR1-RAF) or CDC42 (CDC42 N17 ). After 10 min treatment by HGF/SF and immunoprecipitation of the kinases, the activity of ERK1 and JNK1 were tested using GST-ETS1 1 ± 440 or GST-JUN 1 ± 79 as a substrate. As shown in Figure 5a , phosphorylation of ETS1 by ERK1 in response to HGF/SF was inhibited by the inactive form of RAS or of RAF, but not by the inactive form of CDC42. In contrast, phosphorylation of JUN by JNK1 in response to HGF/SF was inhibited by the inactive form of CDC42, but not by the inactive form of RAS. These data indicate that HGF/SF induced a RAS-ERK and a CDC42-JNK pathway leading to the respective phosphorylation of ETS1 and of JUN.
We then investigated the contribution of these pathways in mediating the EBS/AP1 transcriptional response to HGF/SF. Cells were co-transfected with the EBS/AP1-Luc reporter vector and various combinations of wild type ETS1 (ETS1 1 ± 440 ) and inactive forms of RAS (RAS S186 ), CDC42 (CDC42 N17 ) or RAF (CR1-RAF) (Figure 5b ). Cells were then treated with or without HGF/SF for 24 h, at which time transactivation assays were performed. We found that the inactive form of RAS or RAF, but not of CDC42, decreased the ability of HGF/SF alone or in combination with ETS1 to activate the EBS/AP1 transcriptional response. This con®rms our previous results showing that dominant negative mutant of RAS, but not CDC42, can impair transcriptional response through the c-MET receptor (Tulasne et al., 1999) . These results demonstrate the positive involvement of a RAS-RAF-ERK-ETS1 pathway in mediating a transcriptional response of HGF/SF. For the CDC42-JNK pathway, we recently demonstrated that its role in mediating a transcriptional response to HGF/SF is more complex than previously thought (Paumelle et al., 2000 ; see also Discussion).
HGF/SF induces cell morphogenesis through a RAS-RAF-MEK-ERK signaling pathway
In order to check the functional involvement of this signaling pathway in HGF/SF action, we used U0126 a pharmacological inhibitor of MEK1, the MAP kinase kinase which acts upstream of ERK. Using in vivo kinase assays (see Figure 2b) , we found that phosphorylation of ETS1 by ERK1 in response to ). The following day, cells were treated with (black bars) or without (white bars) HGF/SF (10 ng/ml). At the end of the experiment, luciferase activities were determined in cell extracts Oncogene ETS1 activation by HGF/SF R Paumelle et al HGF/SF was inhibited by U0126, whereas this inhibitor did not prevent phosphorylation of JUN by JNK1 in response to HGF/SF (Figure 6a ). These results demonstrate that HGF/SF activated ERK1 and phosphorylated ETS1 via the RAS-MEK pathway, while the activation of JNK1 and phosphorylation of JUN occur through another pathway. We also found that U0126 inhibited the transcriptional activation of ETS1 (Figure 6b) , the transactivation of a uPA-luc reporter vector (Figure 6c ) and cell morphogenesis in response to HGF/SF (Figure 6d ). The Matrigel substrate allows to show that HGF/SF can induce reorganization of cell clusters in a cellular network, in a time period of 24 h identical to the scattering assay whereas classical morphogenesis assays in collagen gels require several days (Tulasne et al., 1999) . The inhibition of cell morphogenesis induced by HGF/SF using the MEK inhibitor (Figure 6d ) is in agreement with the inhibition of cell scattering that we previously reported (Paumelle et al., 2000) . These data indicate that HGF/SF induces a RAS-RAF-MEK-ERK pathway, which leads to the phosphorylation and activation of ETS1, RAS-dependent transcriptional responses and cell scattering and morphogenesis.
Discussion
The ETS gene family is composed of *30 proteins de®ned by a winged turn-helix-turn DNA binding domain (see Graves and Pertersen, 1998; Laudet et al., 1999) . Within this family, the sequence of ETS1 is ). Twenty-four hours later, cells were placed in MEM medium without FCS for an additional 24 h. The cells were then treated or not with HGF/SF (30 ng/ml) for 10 min. The kinases were immunoprecipitated from the cell lysates using anti-HA or anti-Flag antibodies. Their kinase activities were assayed using GST-ETS1 1 ± 440 or GST-JUN 1 ± 79 as a substrate. Expression of transfected kinases was determined in the cell lysates by immunoblot analysis using either anti-HA antibody (ERK1) or anti-Flag antibody (JNK1). (b) Transactivation assays. Cells were co-transfected with the EBS/AP1-Luc reporter vector and the indicated combination (7, +) of expression vectors encoding either empty, wild type ETS1 (ETS1), inactivated form of RAS (RAS S186 ), CDC42 (CDC42 N17 ) or RAF (CR1-RAF). The following day, cells were treated or not with HGF/SF (10 ng/ml) for 24 h. Transactivation was determined by luciferase assays and results are expressed as the relative luciferase activity ETS1 activation by HGF/SF R Paumelle et al Figure 6 Eect of the U0126 MEK inhibitor on ETS1 phosphorylation, transcriptional activation of ETS1, and morphogenesis in response to HGF/SF. (a) In vivo kinase assays. Cells were transiently transfected with expression vectors encoding wild type HA-ERK1 (ERK1) or FLAG-JNK1 (JNK1). Twenty-four hours after transfection, the cells were placed in MEM medium without FCS for an additional 24 h. Cells were then pretreated with 25 mM of U0126 for 30 min, followed by addition of HGF/SF (30 ng/ml) for 10 min. The kinase activity of HA-ERK1 and FLAG-JNK1 immunoprecipitated from cell lysates was assayed using GST-ETS1
1 ± 440
and GST-JUN 1 ± 79 as a substrate. Expression of HA-ERK1 and Flag-JNK1 were detected by immunoblot analysis as above. (b) Transactivation assays. Cells were co-transfected with a GAL4-Luc reporter vector and an expression vector encoding GAL4-ETS1 1 ± 244 . Twenty-four hours later, the cells were placed in DMEM-0.5% FCS without or with 5 or 25 mM of U0126 for 30 min, and were then treated (black bars) or not (white bars) with 10 ng/ml of HGF/SF for an additional 24 h. Luciferase activities were determined as described above. (c) Transactivation assays. Cells were transfected with the uPA-Luc reporter vector and 24 h later, experiments were performed as described above. (d) Morphogenesis on Matrigel. MDCK cells were seeded on Matrigel. The following day, cells were treated for 30 min with or without 5 or 25 mM U0126, prior addition of HGF/SF (10 ng/ml) for an additional 24 h Oncogene ETS1 activation by HGF/SF R Paumelle et al closely related to ETS2 and to the drosophila ETS factor Pointed P2. In addition to the DNA-binding domain, these proteins share high sequence homology in their N-terminal region, which includes a PLLTP MAP kinase phosphorylation site and a region of *80 amino-acids, the so-called pointed domain. Pointed P2 transcriptional activity is stimulated by the RAS pathway and mutation of the MAP kinase phosphorylation site abrogates this response (Brunner et al., 1994; O'Neill et al., 1994) . In mammals, most studies investigated the involvement of ETS2 as a downstream target of RAS. Indeed, the threonine 72 residue of ETS2 is the target of phosphorylation via activated RAS in NIH3T3 cells (Yang et al., 1996) and in ovarian cell lines (Slupsky et al., 1998) or by the MAP kinase ERK1 and ERK2 activated by CSF-1 in macrophages (Fowles et al., 1998) . Further studies show also ERK-independent phosphorylation of this threonine 72 residue by an AKT-JNK signaling pathway in macrophages (Smith et al., 2000) . Despite its high sequence homology with ETS2, similar knowledge was not available for ETS1. In particular, it was proposed that the kinases which phosphorylate ETS1 in vivo in NIH3T3 cells are not the ERK MAP kinases (Yang et al., 1996) , despite the fact that the threonine 38 residue of ETS1 is phosphorylated by ERK in vitro (Rabault et al., 1996) . Our present study demonstrated that HGF/SF induces the activation of ERK1 leading to the phosphorylation of the threonine 38 residue of ETS1 and that this phosphorylation is required for inducing transcriptional activation of ETS1 in response to HGF/SF in MDCK epithelial cells.
By investigating the speci®city of action of the three MAP kinases, we also found that JNK1 and p38 can phosphorylate ETS1. This phosphorylation was found in vitro using activated recombinant JNK1 and p38 MAP kinases, and in MDCK epithelial cells in basal conditions of stimulation. These results are similar to those obtained with ELK1, one of the best-studied target of RAS within the ETS family. It was found that ELK1 can be phosphorylated in vitro by ERK and JNK and more weakly by p38 MAP kinase (see Treisman, 1996) and that in vivo phosphorylation of ELK1 by MAP kinases is cell type and/or stimuli speci®c. For example, ELK1 phosphorylation was demonstrated in the same CHO cell line, either by EGF-stimulated ERK2 or by IL1-stimulated JNK, which target distinct phosphorylation sites in ELK1 (Whitmarsh et al., 1995; Yang et al., 1998) . In MDCK epithelial cells, phosphorylation of ETS1 by JNK or p38 occurred outside of the threonine 38 residue and was not induced by HGF/SF-stimulated JNK or p38 MAP kinases. Nonetheless, it is possible that dierent stimuli can induce ETS1 phosphorylation via the activation of JNK or p38 MAP kinases in MDCK or other cell types.
Overall, the present study shows that ETS1 together with ETS2 and Pointed P2 form a subset of ETS family proteins, which are downstream eectors of RAS signaling pathway, through speci®c phosphorylation of a PLLTP MAP kinase phosphorylation site in their N-terminal region. This MAP kinase phosphorylation site lies within a¯exible region adjacent to the pointed domain which functions as a structural module (Slupsky et al., 1998) . As recently demonstrated in Drosophila, the pointed domain can favor correct positioning of MAP kinase allowing then speci®c phosphorylation of ETS factors (Baker et al., 2001 ) (see Note added in proof).
Our study also reveals that through another signal transduction pathway than the RAS-RAF-MEK-ERK pathway, HGF/SF can induce JNK activity leading to JUN phosphorylation. This raises the question whether both the RAS-ERK and the CDC42-JNK pathway can mediate the RAS-dependent transcriptional response, implicating EBS/AP1 binding sites. In fact, neither this study nor a previous one using a chimeric MET receptor (Tulasne et al., 1999) , allowed us to demonstrate that a CDC42-JNK pathway stimulates the RAS-dependent transcriptional responses in MDCK epithelial cells. By investigating this further, we found that activation of JNK by HGF/SF through the CDC42-JNK pathway occurs within few minutes and is transient. It is followed within a few hours by a repression of JNK activity by HGF/SF through the RAS-RAF-MEK-ERK pathway and a MAP kinase phosphatase (Paumelle et al., 2000) . Therefore in a delayed manner HGF/SF can repress JNK activity through the RAS-RAF-MEK-ERK pathway. The fact that HGF/SF can sequentially activates and inhibits JNK through distinct signaling pathways renders dicult a straightforward analysis of the role of JNK in mediating biological responses to HGF/SF and will require more careful analysis. This contrasts the commonly observed positive role of the RAS-ERK pathway in mediating HGF/SF action, as reported by us and others (Hartmann et al., 1994; Khwaja et al., 1998 , Paumelle et al., 2000 , Terauchi and Kitamura, 2000 .
This study identi®ed the RAS-RAF-MEK-ERK pathway as a linear transduction pathway leading to activation of ETS1, cell scattering and cell morphogenesis. This was established using the U0126 inhibitor of MEK1. In particular, this inhibitor prevented both cell scattering and morphogenesis, showing the involvement of the same pathway for generating distinct biological responses to HGF/SF. The involvement of ETS1 as a downstream eector of the RAS signaling pathway is well in line with the ability of ETS1 to induce transcription of the uPA protease gene through the EBS/AP1 promoter element (Fafeur et al., 1997) . In agreement with this, stable expression of a dominant negative mutant of ETS1 lacking its transactivation domain inhibited both the expression and activity of uPA and scattering of epithelial cells, including MDCK epithelial cells (Delannoy-Courdent et al., 1998; Kim et al., 2000) . Nonetheless, this does not exclude the possibility that ETS1 can act upstream of the MET signaling pathway. Indeed it was found that enforced expression of ETS1 in MLP epithelial cells increases transcription of the MET receptor and cell scattering (Gambarotta et al., 1996) . Finally, it is important to ETS1 activation by HGF/SF R Paumelle et al emphasize that our results do not mean that the RAS-RAF-MEK-ERK pathway is sucient for triggering all HGF/SF biological responses. A better understanding of the complex cross-talks between the RAS-RAF-MEK-ERK pathway and other pathways implicating signaling proteins, such as the RAC and CDC42 small G proteins (Kodama et al., 1999; Ridley et al., 1995; Zondag et al., 2000) , PI3K (Potempa and Ridley, 1998) or AKT (Xiao et al., 2001 ) and how these pathways are integrated for generating speci®c biological responses represents a real challenge for the future.
Materials and methods
Cell culture, reagents and antibodies
Madin-Darby canine kidney (MDCK) epithelial cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM, Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS) and antibiotics at 378C. Human recombinant form of HGF/SF was purchased from R&D Systems (Minneapolis, MN, USA). The U0126 MEK speci®c inhibitor was purchased from Promega (Madison, WI, USA). Anti-HA rabbit polyclonal antibody (Berkeley Antibody company, Richmond, CA, USA) was used to immunoprecipitate transfected HA-ERK1 and HA-p38. Anti-HA monoclonal antibody (Babco) was used to detect transfected HA-ERK1 and HA-p38 by immunoblot. Transfected Flag-JNK1 was immunoprecipitated using the antiFlag M2 monoclonal antibody and detected by immunoblot using the anti-Flag-M5 monoclonal antibody (Sigma, SaintLouis, MI, USA). The anti phospho-(Thr) MAPK/CDK substrate monoclonal antibody, named anti P-Thr Pro in the text, detects phospho-threonine only when followed by proline and was purchased from New England Biolabs (Beverly, MA, USA).
Plasmids
The ETS1 expression vector (ETS1 1 ± 440 ) encodes the hemaglutinin in¯uenza virus epitope SYPYDVPDYASLGPG (HA) cloned in frame with the murine full-length ETS1 cDNA introduced into the pcDNA3 expression vector. The ETS1 T38A expression vector (ETS1 1 ± 440, T38A ) corresponds to the pcDNA3 ETS1 1 ± 440 expression vector previously described (Fafeur et al., 1997) , with a substitution of the threonine 38 residue to alanine. This substitution was obtained by site-directed mutagenesis by creating a Nar1 synthetic site which substitutes threonine 38 by alanine.
The GAL4-ETS1 expression vector encodes the DNA binding domain of GAL4 (1-147) fused to the N-terminal region of ETS1 containing amino acids 1 to 244 (GAL4-ETS1 1 ± 244 ). The GAL-ETS1 expression vector were constructed by PCR using the cDNA of murine ETS1 (Chen, 1990) , as a template and the following pair of primers: 5'-CCGAATTCATGAAGGCGGCCGTCGATCTCAA-3' and 5'-ACGGATCCACGACTGGCTCTCCCCAGGCACA-3'. The PCR ampli®ed fragment was cloned into EcoR1, BamH1 sites of pCRII (Invitrogen, Griningen, Netherlands) and then digested with EcoR1, BamH1 enzymes and cloned into the same sites of the pGAP424 expression vector in frame with the GAL4 DNA binding domain coding sequence (Defossez et al., 1997) . The GAL4-ETS1
T38A expression vector (GAL-ETS1 T38A ) correspond to the same construct, with a substitution of the threonine 38 residue to alanine; this mutation was obtained as described above. All constructions were veri®ed by nucleotide sequencing.
Other expression vectors were as follows: the pcDNAneo expression vector encoding HA-ERK1 (HA-ERK1) was provided by Dr Philippe Lenorman (CNRS, UMR 6543, Nice). The pcDNA3 encoding Flag-tagged-JNK1 (Flag-JNK1) and the pEXV3 encoding HA-tagged-p38 (HA-p38) were provided by Dr Benoit DeÂ rijard (Centre National de la Recherche Scienti®que, UniteÂ Mixte de Recherche 6543, Nice, France). The pcRSV encoding inactivated RAS (RAS N17 ) was provided by Dr Rayter (Sugen, Redwood City, USA). The pEXV3 encoding another inactivated RAS (RAS S186 ) and the pSG5 encoding the conserved region 1 of RAF (amino acids 128 ± 203 of chicken RAF) (CR1-RAF) were provided by Dr Stephane Ansieau (Max Delbruck Centrum, Berlin, Allemagne). The pMT90 encoding inactivated Myctagged CDC42 (CDC42 N17 ) was provided by Dr Philippe Chavrier (Centre d'Immunologie, Marseille, France).
The reporter vectors used were as follows: the EBS/AP1-Luc reporter contains three tandem copies of polyoma-virus enhancer derived sequence with EBS/AP1-binding sites linked to the thymidine kinase promoter and drives luciferase reporter gene (Fafeur et al., 1997) . The uPA-Luc reporter contains 90-bp HaeIII fragment of the mouse uPA promoter (72446; 72356) linked to the uPA proximal promoter (7114; +398) and drives the luciferase reporter gene (Stacey et al., 1995) . The pGAL4-Luc reporter vector contains ®ve GAL4 binding site linked to a basic promoter element upstream of the luciferase reporter gene (Chang and Gralla, 1993) .
GST fusion protein constructs
The GST-ETS1 bacterial vector encodes the glutathione Stransferase (GST) fused with the 440 amino acids of ETS1 (GST-ETS1 1 ± 440 ). It was constructed by digesting the full coding sequence of the murine ETS1 cDNA into pcDNA3 plasmid with Nae1, Not1 enzymes and cloning into the Sma1, Not1 sites of pGEX4T-1 (Amersham Pharmacia Biotech, Piscataway, NJ, USA) in frame with the GST coding sequence. The GST-ETS1 1 ± 68 and GST-ETS1 1 ± 68, T38A bacterial vectors encode GST fused to the ®rst 68 amino acids of ETS1, with or without a threonine 38 to alanine mutation, (GST-ETS1 1 ± 68 and GST-ETS1 1 ± 68, T38A , respectively). They were constructed by PCR using the cDNA of murine ETS1 and ETS1
T38A , respectively as a template and the following pair of primers, 5'-GCCGAATTCATGAAGGCGGCCGTC-GATCTCAAG-3' and 5'-GACGGATCCTTTGGGGATTC-CCAGTCGCTGCTG-3'. The PCR ampli®ed fragment was cloned into BamH1, EcoR1 sites of pCRII and then digested with EcoR1 enzyme and cloned into EcoR1 site of pGEX4T-1 in frame with the GST coding sequence. All constructions were veri®ed by nucleotide sequencing. The GST-JUN 1 ± 79 bacterial vector was provided by Dr Benoit DeÂ rijard (Centre National de la Recherche Scienti®que, UniteÂ Mixte de Recherche 6543, Nice, France). The GST fusion proteins were expressed in the E. Coli DH5a strain and puri®ed by glutathione anity chromatography (Smith and Johnson, 1988) .
In vitro kinase assays
Puri®ed and activated recombinant ERK1, JNK1 and p38 were purchased from Upstate Biotechnology. Each kinase was incubated for 30 min at 308C with 20 ml of kinase reaction buer (20 mM MOPS pH: 7.2, 7.5 mM MgCl 2 , 25 mM glycerophosphate, 5 mM EGTA, 1 mM Na 3 VO 4 , 1 mM DTT, 50 mM ATP and 10 mM (10 mCi) of (g-33 P) ATP (2000 Ci/mmol) (ICN) containing either myelin basic protein (MBP) (3 mg) (Sigma), GST-JUN (3 mg), GST-ETS1 (10 mg), GST-ETS1 1 ± 68 (10 mg) and GST-ETS1 1 ± 68, T38A
(10 mg) as a substrate. Kinase reactions were stopped by addition of 10 ml of 56Laemmli sample buer. The phosphorylated proteins were resolved by 10% SDS-polyacrylamide gel electrophoresis, dried, and incorporation of [g-33 P]ATP into substrate protein was quanti®ed using Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA) and visualized onto hyper®lms-MP (Amersham, Arlington Heights, IL, USA) by autoradiography.
In vivo kinase assays MDCK cells (4610 5 cells/100 mm-dish) were cultured one day in DMEM-10% FCS and were transiently transfected using the lipofection method (Paumelle et al., 2000) . The following day, cells were grown in serum free minimal Eagle's medium (MEM, Life Technologies). Twenty-four hours later, cells were stimulated for 10 min with 30 ng/ml of HGF/SF. After treatment, cells were washed twice with PBS and suspended in lysis buer (25 mM HEPES pH: 7.5, 100 mM NaCl, 1.5 mM MgCl2, 0.5 mM EGTA, 0.25 mM EDTA, 0.1% NP40, 10 mM NaF) containing freshly added protease and phosphatase inhibitors (20 mM b glycerophosphate, 1 mM Na 3 VO 4 , 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin). Lysates were clari®ed by centrifugation at 48C and protein concentration was determined by BioRad protein assay (Bio-Rad). Appropriate antibodies were incubated on a revolving wheel with 200 mg of total cell lysate overnight at 48C, and then incubated with 20 ml of protein-A sepharose beads (Pharmacia, Piscataway, NJ, USA) for 1 h at 48C. Immune complexes were washed four times with ice-cold lysis buer, and once with kinase buer. Each immunoprecipitate was processed for in vitro kinase assays as described above.
Immunoblot
Cell lysate (20 mg) for direct analysis by immunoblotting were resuspended in Laemmli sample buer, boiled for 5 min and separated onto 10% SDS-polyacrylamide gel and transferred onto PVDF ®lters (Millipore). The membranes were incubated with blocking buer (0.2% v/v caseine, 0.1% v/v Tween-20 dissolved in PBS) for 1 h at room temperature, and probed 1 h at room temperature with appropriate antibodies diluted in blocking buer according to manufacturer's recommendations. After extensive washing in PBS/Tween 0.2%, immune complexes were detected with species speci®c secondary antiserum conjugated with alkaline-phosphatase followed by an enhanced chemiluminescence detection system (Aurora, ICN Biomedical, Cost Mesa, CA, USA).
Transactivation assays
The transactivation assays were performed essentially as described previously (Paumelle et al., 2000) . MDCK cells (3610 4 cells/well) were cultured in 12-well plates for one day. Then, cells were rinsed and incubated in 500 ml of Opti-MEM (Life Technologies-BRL) with a mixture of DNA (2.5 mg/ml) and lipofectamine (20 mg/ml) (Life Technologies-BRL). In each experiment, plates were incubated with the same total amount of plasmid DNA, completed as necessary with the corresponding empty expression vector. After 6 h, 500 ml of Opti-MEM containing 20% of FCS was added, and cells were incubated overnight. The cells were then rinsed and incubated in DMEM 0.5% FCS in the presence or absence of HGF/SF (10 ng/ml). Twenty-four hours later, cells were disrupted in reporter lysis buer (Promega, Madison, WI, USA) and assayed for protein content and luciferase activity. Fold activation is the ratio from each luciferase value, relative to the value from the reporter gene with empty expression vector. Each experiment was repeated at least twice with independent plasmid preparations to assess reproducibility.
Cell morphogenesis assay
Formation of cellular networks on Matrigel gels was performed as follows: MDCK cells (5610 4 cells/well) were plated on a layer of 300 ml of Matrigel (Becton Dickinson) in 24-well plates in DMEM 10% FCS. The next day, cultures were treated with or without 10 ng/ml HGF/SF for 24 h. At the end of the experiments, cells were stained 20 min at 378C with neutral red (0.5% wt/vol), ®xed with 4% paraformaldehyde and their morphology was examined by light microscopy using a Zeiss microscope, equipped with Homan Modulation Contrast objective.
Note added in proof
During the publication process of this manuscript, the role of the pointed domain of ETS1 as an ERK docking site has been elucidated (Seidel and Graves, 2002, Genes Dev., 16, 127 ± 1327) . These data complement our present demonstration that the threonine 38 residue of ETS1 is a phosphoacceptor site for ERK.
